As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, BioSpace reviewed news from companies regarding their deals, pipeline and regulatory updates.

Relay Therapeutics entered a global license and collaboration agreement with Genentech for the commercialization and development of RLY-1971, a potent inhibitor of SHP2.

Four more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.  

Days after Bayer announced a new cell and gene therapy strategy to maximize the capabilities of some recent acquisitions, the Germany-based life sciences giant is jumping into the CAR-T space and expanding the company’s oncology focus through a collaboration with Bay Area-based Atara Biotherapeutics.

Urovant Sciences and Genmab reported disappointing clinical trial announcements.

Merck & Co. Inc. agreed to acquire privately held VelosBio Inc. for $2.75 billion in cash, in a move that will help strengthen the company’s cancer drug portfolio.

While the world has largely been focused on the development of vaccines and therapeutics for Covid-19, the U.S. Food and Drug Administration has remained busy lining up potential approvals of medications for other diseases and illnesses.

Shares of Karyopharm Therapeutics climbed in trading after the company announced positive topline results in a Phase III study of Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, which sets up potential approval in this indication.

Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).

Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% (programmed death-ligand 1).